Look­ing to con­quer new ter­ri­to­ries, Or­biMed joins a $60M bet on a Bio­haven spin­out in Shang­hai

Close to 2 years af­ter Bio­haven boot­ed up its own Shang­hai-based spin­out to take its drugs to the Chi­nese mar­ket, they’re fol­low­ing up with a $60 mil­lion ven­ture round to fund the pipeline work in the gi­ant Asian mar­ket — and they now have the ex­ec­u­tive crew to lead the way.

Or­biMed stepped up to lead the round for BioShin, an­nounced Mon­day. And the pow­ers that be at Vlad Coric-helmed Bio­haven, which laid the ground­work for BioShin in late 2018, al­so tapped 2 staffers for the top posts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER